Medical Evidence on Tirzepatide

Authors: Maple, K. and Monis, A.

Date: September 2024

Abstract

Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor antagonist has emerged as a promising therapeutic agent for managing type 2 diabetes and obesity. The peptide also provides benefits for the cardiovascular system through a favorable impact on lipid profiles and reductions in cardiovascular risk factors. The primary objective of this white paper is to analyze existing evidence and clinical trial data to provide a comprehensive understanding of tirzepatide's therapeutic potential in metabolic disorders and cognitive function.

Table of Contents

Introduction

Tirzepatide is an amino acid peptide that was designed for weight loss and the treatment of type 2 diabetes. There are two brands that have been approved by the FDA, including Zepbound and Mounjaro. More precisely, the US Food and Drug Administration approved Mounjaro on May 13, 2022, while Zepbound gained its FDA approval on November 8, 2023.

The peptide mainly works by reducing appetite, which is a common concern in obesity. The medication activates receptors of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), incretins i.e. hormones secreted from the intestine, to decrease appetite and food intake. It also shows potential in slowing down the rate at which food moves through the gastrointestinal tract. By postponing stomach emptying, incretins delay the release of blood glucose into the bloodstream thereby promoting satiety. Tirzapetide is also a treatment that can effectively increase the release of insulin when blood glucose levels increase. The medication acts on incretins such as GLP-1. Incretins work by encouraging the pancreas to release insulin and inhibit glucagon, a hormone that would otherwise act on the liver to release stored glucose thus increasing blood sugar levels. This makes it a potential therapeutic agent for patients with type 2 diabetes.

It's recommended to use Tirzepatide alongside diet and exercise for efficient results. The medication is administered by injection under the skin once a week.

Problem Statement

Type 2 diabetes is considered a global public health pandemic, with the prevalence continuously rising. At the same time, there's a consistent increase in the rate of obesity noted worldwide. Excess weight results in a higher risk of type 2 diabetes, and in patients with this disease, weight loss isn't easy. This creates a vicious cycle between obesity and diabetes.

Current treatments focus on regulating blood glucose regulation through different pathways. GLP-1 analogs have also become a common treatment in type 2 diabetes patients who are obese. However, pharmaceutical options can sometimes result in side effects, which is why the safety of new potential therapies needs to be considered.

Literature Review

Numerous clinical trials and research papers have explored the use of Tirzepatide as an alternative to current GLP-1 analogs, with a particular focus on its effects on weight loss, blood glucose regulation, and overall safety profile. J. Andraos et al. compared Tirzepatide to existing pharmaceutical treatments, emphasizing its relationship to GLP-1 analogs. Y.K. Cho et al. provided a comprehensive analysis of Tirzepatide's impact on the cardiovascular system, highlighting safety considerations and potential side effects. X. Guo et al. delved into the cognitive effects that Tirzepatide may have on patients.

W.T. Garvey conducted a phase 3 double-blind, randomized, controlled trial to assess the efficacy and safety of Tirzepatide versus placebo for weight management in individuals with obesity and type 2 diabetes. Similarly, A.M. Jastreboff's phase 3 trial investigated Tirzepatide's effectiveness in people with obesity. The focus on type 2 diabetes was central to the study by J.P. Frias et al., who led a double-blind, placebo-controlled trial to evaluate the medication's effectiveness in managing the condition.

T.A. Wadden et al. examined Tirzepatide's effectiveness following intensive lifestyle interventions for overweight or obese subjects as part of the SURMOUNT-3 phase 3 trial. L.J. Aronne et al. extended this exploration in the SURMOUNT-4 trial, studying whether weekly subcutaneous doses of Tirzepatide, combined with diet and exercise, help maintain weight loss in overweight or obese participants and whether withdrawal from the medication would lead to weight regain.

P.J. Rodriguez and T. Karagiannis et al. compared the efficacy of Tirzepatide and semaglutide in adults with overweight or obesity, a focus echoed in the open-label phase 3 trial led by J.P. Frias et al., which specifically assessed these medications in patients with type 2 diabetes.

In addition to studies on weight loss and type 2 diabetes, J.W. Skelley et al. examined the impact of Tirzepatide and GLP-1 agonists on the effectiveness of oral hormone contraception. Finally, L. Liu's research focused primarily on the safety profile of Tirzepatide, further contributing to understanding the medication's risk factors and tolerability.

These studies collectively offer a robust overview of Tirzepatide's efficacy, safety, and broader potential in managing conditions like obesity and type 2 diabetes, while also revealing its implications for other health areas.

Methodology

This white paper considers previous studies and review papers that have been published in major journals. It explores the potential therapeutic benefits of tirzepatide as an agent for type 2

diabetes, weight loss, and improved cognition. The paper also considers how safe this peptide is in cases of obesity and type 2 diabetes, focusing on its potential impact on various systems in the human body.

Results/Findings

J. Andraos et al. compare the use of tirzepatide to GLP-1 analogs, focusing on its glucose-lowering effects and potential for weight loss. They found that tirzepatide is more potent than standard GLP-1 analogs commonly used to treat type 2 diabetes, providing enhanced benefits for patients aiming to reduce excess weight and improve glucose control.

Y.K. Cho et al. examined tirzepatide's impact on the cardiovascular system, noting that the peptide has a well-established safety profile, particularly concerning cardiovascular diseases. Beyond weight loss and glucose regulation, they highlighted tirzepatide's dual agonist actions, which provide additional cardiovascular benefits by regulating glucose levels and producing anti-inflammatory effects.

X. Guo et al. explored tirzepatide's effects on cognition, particularly in diabetic models. They found that tirzepatide helped reduce memory impairments often associated with diabetes, primarily through improved blood glucose regulation and decreased inflammation.

In a double-blind, randomized, multicenter, placebo-controlled phase 3 trial, W.T. Garvey et al. evaluated 1,514 adults with a BMI of 27 kg/m² or higher over a 72-week period. Subjects who received weekly doses of tirzepatide (10mg or 15mg) experienced significant weight loss, while the safety profile of tirzepatide was comparable to other incretin-based therapies.

A clinical trial led by A. Jastreboff et al. enrolled 2,539 adults who were randomized to receive tirzepatide (5mg, 10mg, 15mg) or placebo over 72 weeks. The study found substantial weight reductions across all dosage groups, with weight loss of -15% at 5mg, -19.5% at 10mg, and -20.9% at 15mg. The most frequent side effects were gastrointestinal, yet the overall conclusion confirmed tirzepatide's effectiveness in promoting weight loss.

J.P. Frias et al. conducted a 12-week study with 111 patients randomized to receive either tirzepatide (12mg or 15mg) or placebo. They observed significant reductions in HbA1c among those receiving tirzepatide, indicating its potential in managing type 2 diabetes. Lower starting doses and gradual increases were associated with a more favorable side effect profile.

T.A. Wadden et al. reported a weight reduction of approximately -18.4% over 72 weeks in patients treated with tirzepatide, compared to just -2.5% in the placebo group. Tirzepatide also provided significant additional weight loss in participants who had already achieved ≥5% weight reduction through lifestyle interventions.

L.J. Aronne et al. studied the effects of tirzepatide withdrawal, finding that patients who discontinued the medication regained a significant portion of their lost weight, while those who continued treatment maintained or even augmented their initial weight loss. After 36 weeks of tirzepatide use, participants lost 20.9% of their body weight, but those switched to placebo regained 14%.

Several studies compared tirzepatide and semaglutide for their effectiveness in weight loss and type 2 diabetes management. P.J. Rodriguez et al. found that tirzepatide led to more significant weight loss, with higher percentages of patients achieving 5%, 10%, and 15% body weight reductions compared to semaglutide. This effect was consistent across patients with and without type 2 diabetes.

T. Karagiannis et al. analyzed 28 trials involving 23,622 participants, concluding that tirzepatide 15mg was the most effective treatment for reducing HbA1c and body weight, surpassing semaglutide. However, both drugs were associated with an increased risk of gastrointestinal side effects at higher doses.

J.P. Frias et al. conducted an open-label trial comparing weekly doses of tirzepatide (5mg, 10mg, 15mg) to semaglutide (1mg) in 1,879 patients with type 2 diabetes. Results showed that tirzepatide was non-inferior to, and in some cases superior to, semaglutide across all dosages.

In a separate area of research, J.W. Skelley et al. examined tirzepatide's influence on the absorption of oral hormonal contraceptives, finding that tirzepatide had a greater impact on contraceptive efficacy compared to other medications in this class.

L. Liu focused on tirzepatide's safety profile, analyzing data from the FDA Adverse Event Reporting System (FAERS) database between 2022 and 2023. Out of 1,904,481 adverse event reports, tirzepatide was linked to 20,043 cases, with 67.92% of these occurring in females. The highest risk of side effects was in the 50-59 age group, followed by those aged 40-49 and 60-69. Common side effects included gastroesophageal reflux disease, dyspepsia, and vomiting, along with some cases of incorrect dosage, injection site hemorrhage, and procedural complications.

In summary, the studies collectively highlight tirzepatide's robust efficacy in weight loss, type 2 diabetes management, and its broader therapeutic potential. The medication has demonstrated significant advantages over GLP-1 analogs like semaglutide, although safety considerations, particularly gastrointestinal side effects, warrant further investigation.

Discussion

This white paper reviewed several studies that offer insights into the potential benefits of Tirzepatide for patients with obesity and type 2 diabetes. Tirzepatide has already received FDA approval for the treatment of obesity, particularly in cases where related medical conditions are present, as well as for managing type 2 diabetes. Ongoing research continues to assess its long-term efficacy and safety, aiming to provide more comprehensive data on the peptide's sustained effects over time.

Conclusion

Tirzepatide has emerged as a promising alternative to traditional GLP-1 receptor agonists, offering enhanced benefits through its dual action on GLP-1 and GIP receptors. This dual mechanism has shown superior efficacy in weight management and glycemic control, making it

highly effective for patients with obesity and type 2 diabetes. By reducing appetite and enhancing insulin sensitivity, Tirzepatide leads to significant weight loss and improved blood sugar regulation. In clinical trials, patients treated with Tirzepatide experienced greater reductions in body weight and HbA1c levels compared to those treated with GLP-1 analogs, such as semaglutide.

Tirzepatide's safety profile is also favorable, with studies showing fewer gastrointestinal side effects when doses are titrated gradually. Beyond its metabolic benefits, Tirzepatide is being explored for its potential cognitive benefits. Research suggests that the medication may reduce memory impairments in diabetic patients by improving glucose regulation and reducing inflammation, both of which are crucial for maintaining brain health. Its anti-inflammatory effects protect neurons from damage associated with chronic hyperglycemia, offering potential in conditions like Alzheimer's disease.

The broader systemic benefits of Tirzepatide, including improvements in cholesterol levels, liver fat reduction, and cardiovascular health, make it a versatile therapeutic agent. Its dual mechanism addresses multiple metabolic pathways, providing added benefits over traditional GLP-1 medications. While already approved for treating type 2 diabetes and obesity, ongoing research is assessing its long-term efficacy and safety, particularly regarding weight maintenance and potential applications in cognitive disorders.

In summary, Tirzepatide represents a major advancement in the treatment of obesity and type 2 diabetes, offering superior outcomes in weight loss, glycemic control, and cognitive health. Its versatility and potential for broader applications make it a promising option for managing metabolic disorders and related health challenges.

References

Dhirani D, Shahid A, Mumtaz H. A new kind of diabetes medication approved by the FDA: is there hope for obesity?. *Int J Surg*. 2023;109(2):81-82. Published 2023 Feb 1. doi:10.1097/JS9.0000000000000044

FDA Approves New Medication for Chronic Weight Management. *FDA*. Published 2023 Nov.

Andraos J, Muhar H, Smith SR. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues. Rev Endocr Metab Disord. 2023 Dec;24(6):1089-1101. doi: 10.1007/s11154-023-09825-1. Epub 2023 Aug 1. PMID: 37526853; PMCID: PMC10697893.

Cho YK, La Lee Y, Jung CH. The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist. J Lipid Atheroscler. 2023 Sep;12(3):213-222. doi: 10.12997/jla.2023.12.3.213. Epub 2023 Jul 19. PMID: 37800107; PMCID: PMC10548186.

Guo X, Lei M, Zhao J, Wu M, Ren Z, Yang X, Ouyang C, Liu X, Liu C, Chen Q. Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin

resistance and inflammation response in diabetic rats. Front Pharmacol. 2023 Aug 28;14:1146960. doi: 10.3389/fphar.2023.1146960. PMID: 37701028; PMCID: PMC10493299.

Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet*. 2023;402(10402):613-626. doi:10.1016/S0140-6736(23)01200-X

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med*. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038

Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22(6):938-946. doi:10.1111/dom.13979

Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial [published correction appears in Nat Med. 2024 Jun;30(6):1784. doi: 10.1038/s41591-024-02883-1]. *Nat Med*. 2023;29(11):2909-2918. doi:10.1038/s41591-023-02597-w

Aronne LJ, Sattar N, Horn D, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity. The SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945

Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. *JAMA Intern Med*. Published online July 8, 2024. doi:10.1001/jamainternmed.2024.2525

Karagiannis T, Malandris K, Avgerinos I, et al. Subcutaneously administered tirzepatide vs. semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Diabetologia. 2024;67:1206-1222. doi: 10.1007/s00125-024-06144-1

Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. doi: 10.1056/NEJMoa2107519

Skelley JW, Swearengin K, York AL, Glover LH. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. *J Am Pharm Assoc (2003)*. 2024;64(1):204-211.e4. doi:10.1016/j.japh.2023.10.037

Liu L. A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database. *Front Pharmacol*. 2024;15:1397029. Published 2024 Jun 7. doi:10.3389/fphar.2024.1397029

Appendices



Andraos, J., Muhar, H., & Smith, S. R. (2023). Beyond glycemia: Comparing tirzepatide to GLP-1 analogues. *Reviews in Endocrine & Metabolic Disorders*, *24*(6), 1089-1101. https://doi.org/10.1007/s11154-023-09825-1



Guo, X., Lei, M., Zhao, J., Wu, M., Ren, Z., Yang, X., Ouyang, C., Liu, X., Liu, C., & Chen, Q. (2023). Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats. *Frontiers in Pharmacology*, *14*. https://doi.org/10.3389/fphar.2023.1146960



Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22(6):938-946. doi:10.1111/dom.13979



Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial [published correction appears in Nat Med. 2024 Jun;30(6):1784. doi: 10.1038/s41591-024-02883-1]. *Nat Med*. 2023;29(11):2909-2918. doi:10.1038/s41591-023-02597-w

Acknowledgments
This whitepaper was made possible by previous research conducted by J. Andraos, Y.K. Cho, X. Guo et al. The authors would like to thank these researchers for the work they have done and for sharing the findings of their studies.

Conflicts of Interest
There are no conflicts of interest that the authors of this white paper declared.

Contact Information
For any inquiries regarding this whitepaper, please contact the authors directly.